Literature DB >> 26930419

Rosuvastatin: Beyond the cholesterol-lowering effect.

Francesca Cortese1, Michele Gesualdo2, Annamaria Cortese3, Santa Carbonara2, Fiorella Devito2, Annapaola Zito2, Gabriella Ricci2, Pietro Scicchitano2, Marco Matteo Ciccone2.   

Abstract

Rosuvastatin is a fully synthetic statin wich acts by interfering with the endogenous synthesis of cholesterol through competitively inhibiting the 3-hydroxy-3-methylglutaryl coenzyme A reductase, a liver enzyme responsible of the rate-limiting step in cholesterol synthesis. When compared to other molecules of the same class, it shows high efficacy in the improvement of lipid profile, and, thanks to its non-cholesterol-lowering actions (anti-inflammatory, antioxidant and antithrombotic), represents a crucial tool for cardiovascular primary and secondary prevention. Moreover, recent data highlight rosuvastatin beneficial effects in several other fields. In this manuscript we analyzed literature sources in order to better define rosuvastatin features and discuss some critical issues.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Cholesterol (PubChem CID: 5997); Coenzyme Q10 (PubChem CID: 5281915); Farnesylpyrophosphate (PubChem CID: 44134714); Geranylgeranylpyrophosphate (PubChem CID: 44134732); Lipid-lowering effect; Mevalonate (PubChem CID: 4478250); Nitric Oxide (PubChem CID: 145068); Pleiotrophic effect; Rosuvastatin; Rosuvastatin (PubChem CID:446157)

Mesh:

Substances:

Year:  2016        PMID: 26930419     DOI: 10.1016/j.phrs.2016.02.012

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  14 in total

1.  Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study.

Authors:  Iveta Merćep; Ivana Radman; Vladimir Trkulja; Tamara Božina; Livija Šimičević; Ema Budimir; Lana Ganoci; Nada Božina
Journal:  Eur J Clin Pharmacol       Date:  2021-10-19       Impact factor: 2.953

2.  Is rosuvastatin protective against sepsis-associated encephalopathy? A secondary analysis of the SAILS trial.

Authors:  Shi-Yuan Yu; Zeng-Zheng Ge; Jun Xiang; Yan-Xia Gao; Xin Lu; Joseph Harold Walline; Mu-Bing Qin; Hua-Dong Zhu; Yi Li
Journal:  World J Emerg Med       Date:  2022

3.  Association between Statin Use and Meniere's Disease: Results from a National Health Screening Cohort.

Authors:  So Young Kim; Dae Myoung Yoo; Chanyang Min; Hyo Geun Choi
Journal:  Int J Environ Res Public Health       Date:  2021-08-17       Impact factor: 3.390

4.  Nuclear Factor Erythroid 2 Related Factor 2 Activator JC-5411 Inhibits Atherosclerosis Through Suppression of Inflammation and Regulation of Lipid Metabolism.

Authors:  Xinhai Jiang; Yining Li; Weizhi Wang; Xiaowan Han; Jiangxue Han; Mingzhu Chen; Jing Zhang; Chenyin Wang; Shunwang Li; Jinque Luo; Xiao Wang; Yang Xu; Yanni Xu; Jingcai Cheng; Shuyi Si
Journal:  Front Pharmacol       Date:  2020-11-16       Impact factor: 5.810

5.  Short- and long-term effects on reproductive parameters of female Wistar rats after exposure to rosuvastatin starting in pre-puberty.

Authors:  Jorge W F Barros; Karolina S Tonon; Cibele S Borges; Patrícia V Silva; Ana F Q Lozano; Tainá L Pacheco; Janete A Anselmo-Franci; Wilma G Kempinas
Journal:  Curr Res Toxicol       Date:  2020-11-27

6.  Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers.

Authors:  Hyungsub Kim; Hee Youn Choi; Yo-Han Kim; Kyun-Seop Bae; Jina Jung; Hankil Son; Hyeong-Seok Lim
Journal:  Drug Des Devel Ther       Date:  2018-04-11       Impact factor: 4.162

Review 7.  Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond.

Authors:  Dimitrios Tsikas
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

8.  Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Authors:  Angie M Torres-Adorno; Heidi Vitrac; Yuan Qi; Lin Tan; Kandice R Levental; Yang-Yi Fan; Peiying Yang; Robert S Chapkin; Bedrich L Eckhardt; Naoto T Ueno
Journal:  Oncogene       Date:  2018-11-20       Impact factor: 9.867

Review 9.  Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging.

Authors:  Elena Barbu; Mihaela-Roxana Popescu; Andreea-Catarina Popescu; Serban-Mihai Balanescu
Journal:  Int J Mol Sci       Date:  2022-01-16       Impact factor: 5.923

10.  Rosuvastatin Induces Renal HO-1 Activity and Expression Levels as a Main Protective Mechanism against STZ-Induced Diabetic Nephropathy.

Authors:  Gehan H Heeba; Marwa A M Ali; Azza A K El-Sheikh
Journal:  Medicina (Kaunas)       Date:  2022-03-15       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.